ZINDACLIN LICENSING COLLABORATIONS EXTENDED TO INCLUDE ITALY AND SPAIN

A A

ULURU INC. ("ULURU") who has signed a definitive merger agreement with Oxford Ventures, Inc. (OTCBB:OXFV) today announced the expansion of the European licensing of Zindaclin to include Italy and Spain. ProStrakan Ltd., the worldwide licensee of our ResiDerm(TM) technology, from which Zindaclin(R) was developed have sub-licensed the marketing rights for Italy and Spain to Cantabria Farmaceutica ("Cantabria") a Spanish company with operations in Southern Europe.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1112253XSL_NEWSML_TO_NEWSML_WEB.xml)